Roivant Sciences Ltd. ROIV
40.64 USD -1.21 (-2.89%)
Nov 12, 2026, 1:34 PM EST
40.48 Day range 41.50
19.96 52-week range 42.50
- YTD
- +87.28%
- 1 year
- +90.62%
News
seekingalpha.com Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in…
globenewswire.com Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized,…
benzinga.com Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday Analysts adjusted targets: RIOT upgraded to Buy; WIX downgraded to Underperform; targets also changed for MNDY, ONTO, ROIV, FERG and NVDA.
benzinga.com HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48 HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $47 to $48.
defenseworld.net Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position CenterBook Partners LP decreased its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 35.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
seekingalpha.com Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 9, 2026 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO &…
marketbeat.com Roivant Sciences Q2 Earnings Call Highlights Roivant Sciences NASDAQ: ROIV reported $31 million in net revenue from the initial launch of LISRAYA and said an experimental rheumatoid arthritis treatment met its primary endpoint in a randomized…
zacks.com Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.41.
benzinga.com Roivant Sciences Q2 2027 Earnings Call Transcript Roivant Sciences (NASDAQ:ROIV) reported second-quarter financial results on Monday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought…
globenewswire.com Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially…
globenewswire.com Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
defenseworld.net Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of…
defenseworld.net Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of…
benzinga.com Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.08% on an annualized basis producing an average annual return of 35.57%. Currently, Roivant Sciences has a…
benzinga.com Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56 Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.
benzinga.com If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.86% on an annualized basis producing an average annual return of 37.68%. Currently, Roivant Sciences has a…
benzinga.com Why Is Roivant Sciences Stock Surging Wednesday? Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a…
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
benzinga.com Transcript: Roivant Sciences Q1 2027 Earnings Conference Call On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a…
benzinga.com Immunovant Ends Autoimmune Skin Disorder Program Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.- benzinga.com Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
benzinga.com This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
benzinga.com Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51 Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.- benzinga.com TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55 TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.
benzinga.com Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46 Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.
benzinga.com HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47 HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.
benzinga.com S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
- benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
- benzinga.com Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52 Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $52.
benzinga.com Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
benzinga.com Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distance and reduced cardiac strain in PH-ILD.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
benzinga.com Roivant Announces Results From Its Phase 2 PHocus Clinical Trial Evaluating Mosliciguat For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; PHocus Met Its Primary Endpoint, Demonstrating Clinically Meaningful And Statistically Significant Placebo-Adjusted Reduction In Pulmonary Vascular Resistance "PH-ILD remains one of the most challenging forms of pulmonary hypertension to treat, given the heterogeneity of the disease and the fact that existing therapies are approved in limited geographies…
benzinga.com FDA Clears First Targeted Dermatomyositis Treatment From Roivant FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.- benzinga.com HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
benzinga.com Why Is Arbutus Biopharma Stock Gaining Friday? Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46 Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.- benzinga.com Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42 Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.
- benzinga.com HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41 HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $34 to $41.
- benzinga.com Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of…
benzinga.com Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.- benzinga.com Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36 Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $30 to $36.
benzinga.com TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $41 TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $38 to $41.- benzinga.com HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $34 price target.